Indena Enhances Developments in Custom Synthesis

Oct 04, 2017
By Pharmaceutical Technology Editors

Indena announced that it will be completing the construction of a new GMP kilolab for highly potent APIs (HPAPIs). The suite is designed to handle substances requiring an occupational exposure limit (OEL) between 20 and 50 ng/m3. With the new high-containment kilolab, Indena will have the technical capacity to handle a greater range of compound classes, including derivatives from fermentation and total synthesis. Indena remains firmly attached to its know-how of natural and semi-synthetic substances, but with the high-containment facility built for the production of highly toxic active ingredients, the company will be able to extend its range of custom synthesis to include cytotoxic offerings. Indena will be exhibiting at CPhI Worldwide, in Frankfurt, Germany from October 24–26, 2017. 

Source: Indena, Booth 8.0F30

native1_300x100
lorem ipsum